Recorded: Thursday, February 23rd
Share the Science Series
Watch this webinar to hear Dr. Miguel-Angel Perales, M.D., discuss the factors influencing immune recovery post allogeneic HCT, the clinical consequences of delayed immune recovery post allogeneic HCT, and the potential strategies to enhance immune recovery post allogeneic HCT.
Allogeneic hematopoietic stem cell transplant (HCT) is an established treatment for hematologic malignancies. However, it is associated with significant adverse events, including infection, relapse, and graft-versus-host disease (GVHD). An important variable that may affect these outcomes is the recovery of the immune system after transplant.
HCT is complicated by post-transplant immune deficiency, which is more profound after allogeneic than autologous HCT. Cytoreductive conditioning regimens containing chemotherapy and/or radiation eliminate tumor cells but also significantly deplete patient immune systems, particularly cells of the lymphoid lineage, and allow for successful engraftment of hematopoietic stem cells (HSC) in the bone marrow niche. While the depletion of the adaptive immune system promotes engraftment as it prevents host cells from attacking donor stem cells, delayed lymphoid recovery following immune depletion is associated with morbidity and mortality and can potentially also lead to malignant relapse. Post-transplant immune depletion is particularly striking within the T cell compartment, which is extremely sensitive to negative regulation and remains depressed for a considerable time. Consequently, regeneration of the immune system remains a significant unmet clinical need.
There are currently no FDA-approved strategies for immune reconstitution. However, several preclinical and clinical studies have identified promising therapeutic strategies for immune regeneration. In this presentation, we will review immune reconstitution following HCT, with a particular emphasis on factors that contribute to delayed immune recovery post transplant, including graft source, and the clinical consequences. We will also discuss current clinical and research assays to monitor post-HCT immune recovery and highlight some of the potential strategies that are currently under investigation to enhance immune recovery in HCT recipients.
Attendees will learn:
- Gain knowledge of factors influencing immune recovery post allogeneic HCT, including graft source
- Understand clinical consequences of delayed immune recovery post allogeneic HCT
- Learn about novel potential strategies to enhance immune recovery post allogeneic HCT
Attention: The audio portion of this Share the Science “live edition” was recorded at 2017 BMT Tandem so you will have to manually advance the slides with the audio trak. Complete the form to download the presentation.
Dr. Miguel-Angel Perales, M.D.
Dr. Perales is the Deputy Chief of the Adult Bone Marrow Transplantation Service and the Director of the Adult Bone Marrow Transplant Fellowship Program at Memorial Sloan Kettering Cancer Center in New York. He is an Associate Professor of Medicine at Weill Cornell Medical College. He is a member of the Board of Directors of Be The Match (National Marrow Donor Program – NMDP) and serves on committees for several organizations including the American Society for Blood and Marrow Transplantation (ASBMT), the American Society of Hematology (ASH), the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), the Center for International Blood and Marrow Transplant Research (CIBMTR), and the Alliance for Clinical Trials in Oncology (CALGB). He is the co-chair for the ASBMT educational committee and co-chair for the Graft Sources and Manipulation Working Committee for the CIBMTR, where he also serves as a member at Large (North America) for the Advisory Committee, and is a member of the American Association for Cancer Research (AACR) Cancer Immunology Working Group (CIMM) Steering Committee. Dr. Perales has over 130 publications including peer-reviewed articles, position papers, guidelines, book chapters, editorials and invited reviews. He has been an invited speaker at numerous national and international seminars over the past fifteen years. Dr. Perales received his MD at the Free University of Brussels. His postdoctoral training was completed at the Tufts Medical Center and Memorial Sloan Kettering Cancer Center.